Catatonic and Non-Catatonic Neuroleptic Malignant Syndrome

Australian and New Zealand Journal of Psychiatry

Volumn 34, Issue 5, 2000, Pages 877-

  Lee, Joseph W Y ^a  

^a GRAYLANDS HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; NEUROLEPTIC AGENT;

AFFECTIVE NEUROSIS; CATATONIA; CLINICAL FEATURE; CLINICAL PRACTICE; DEPRESSION; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; ELECTROCONVULSIVE THERAPY; HUMAN; LETTER; MANIA; MEDICAL LITERATURE; MEDICAL RESEARCH; MOTOR DYSFUNCTION; NEUROLEPTIC MALIGNANT SYNDROME; PARKINSONISM; PATHOGENESIS; PREDICTION; RISK FACTOR; SYMPTOMATOLOGY;

ANTI-ANXIETY AGENTS, BENZODIAZEPINE; ANTIPSYCHOTIC AGENTS; CATATONIA; DISEASE MANAGEMENT; ELECTROCONVULSIVE THERAPY; HUMAN; NEUROLEPTIC MALIGNANT SYNDROME;

EID: 0033809322     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1080/j.1440-1614.2000.0822j.x     Document Type: Letter

References (5)

1. Trollor JN, Sachdev PS. Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases. Australian and New Zealand Journal of Psychiatry 1999; 33:650–659.
2. Fink M. Neuroleptic malignant syndrome and catatonia: one entity or two? Biological Psychiatry 1996; 39:1–4.
3. Lee JWY. Serum iron in catatonia and neuroleptic malignant syndrome. Biological Psychiatry 1998; 44:499–507.
4. Fricchione GL, Cassem NH, Hooberman D, Hobson D. Intravenous lorazepam in neuroleptic-induced catatonia. Journal of Clinical Psychopharmacology 1983; 3:338–342.
5. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edn. Washington: American Psychiatric Association, 1994.